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Background: The association between obesity and lung cancer (LC) remains poorly
understood. However, other indices of obesity on the basis of body shape instead of body
size have not been examined yet. The aim of this study was to evaluate the association
between different indices of body size and body shape and the risk of LC. In particular, this
study examined the association between A Body Shape Index, a more precise indicator of
abdominal fat than traditional anthropometric measures, and the risk of LC.
Methods: In the prospective cohort the Rotterdam Study, we analysed data of 9,689
participants. LC diagnoses were based on medical records and anthropometric
measurements were assessed at basel ine. Cox-regression analyses with
corresponding Hazard Ratios were used to examine the association between the
anthropometric measurements and the risk of LC with adjustment for potential
confounders. Potential non-linear associations were explored with cubic splines using
the Likelihood ratio (LR) test.
Results: During follow-up, 319 participants developed LC. Body mass Index (BMI) was
inversely associated with the risk of lung cancer (HR 0.94, 95% CI: 0.91–0.97) and
persisted after excluding lung cancer cases during the first 10 years of follow-up. There
was evidence for a non-linear association between BMI and the risk of lung cancer (0,04,
df = 1), which indicated that the inverse association between BMI and lung cancer was
mainly present in non-obese participants. Waist circumference (WC) (HR 1.03 95% CI:
1.01–1.05), Waist-to-Hip Ratio (WHR) (HR 1.23 95% CI: 1.09–1.38) and ABSI (A Body
Shape Index) (HR 1.17 95% CI: 1.05–1.30) were positively and linearly associated with the
risk of lung cancer.
Conclusions: Body shape rather than body size may be an important risk indicator of LC.
Future research should focus on the role of visceral fat and the risk of LC as well as the
underlying mechanisms.
Keywords: waist-to-hip ratio (WHR), waist circumference (WC), body mass index (BMI), A Body Shape Index (ABSI),
lung cancer risk, obesityNovember 2020 | Volume 10 | Article 5911101
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Lung cancer is currently the main cause of cancer mortality
worldwide (1). In 2018, the number of incident lung cancer cases
was approximately 2.9 million worldwide, accompanied by 1.75
million cases of death by lung cancer (2, 3). Apart from smoking,
emerging evidence shows that obesity may play a role in the
development of cancer. Although obesity is associated with 13
types of cancer (4), the association between obesity and lung
cancer remains controversial and the underlying mechanisms are
poorly understood.
Several indices of nutritional status exist. The most
commonly used method is Body Mass Index (BMI) due to its
simplicity of measuring and low cost (5). Several meta-analyses
have shown an inverse association between BMI and the risk of
lung cancer (6–9). A first explanation may come from residual
confounding by smoking. Multiple studies that assessed the role
of residual confounding by restricting the association between
BMI and the risk of lung cancer to never smokers were not able
to fully explain the inverse association between BMI and lung
cancer (9–13). A second explanation for this inverse association
may be due to weight loss as a result of preclinical lung cancer or
an impaired lung function e.g. by chronic obstructive lung
disease (14). It has been suggested that the association of BMI
and lung cancer should increase to a more positive association
after excluding lung cancer cases during the first years of the
follow-up which may include imminent cases of lung cancer.
However, several studies that excluded lung cancer cases in the
first years of follow-up have found inconsistent results (9, 15–20).
In contrast to overall obesity and body size, as measured by
BMI, specifically abdominal obesity may have a more important
role in lung cancer development (9, 21–23). Abdominal obesity as
a measure of body shape can be reflected by an increased Waist-
to-Hip Ratio (WHR) and Waist circumference (WC),
independent of BMI (24, 25). A meta-analysis, including seven
prospective cohorts, has showed that WC and WHR were
positively associated with the risk of lung cancer (21). However,
this meta-analysis consisted of mainly women and measurements
were mostly self-reported and/or self-measured. Meanwhile, more
recent studies with larger sample sizes have shown more
controversial results; a pooled analysis of 12 cohorts has
concluded that both WC and WHR were positively associated
with the risk of lung cancer (9), whereas another prospective
cohort study has found an inverse association for WC and the risk
of lung cancer in Chinese participants (23), and a study among
162.679 American adults has found no association between BMI
and WC with the risk of lung cancer (22).
A newly developed anthropometric measurement is A Body
Shape Index (ABSI), combining WC to BMI and weight into one
formula (26). Studies have shown that ABSI is an independent
predictor of the fat and fat free mass ratio (27), indicating that
ABSI may be a more precise indicator of abdominal fat.
Moreover, a meta-analysis has shown that ABSI outperformed
BMI and WC in predicting all-cause mortality including cancer
(28). However, to the best of our knowledge, the association
between ABSI and the risk of lung cancer has not been
examined yet.Frontiers in Oncology | www.frontiersin.org 2The objective of this study was to evaluate the different indices
of body size (i.e. BMI) and body shape (i.e. WC, WHR, and
ABSI) and the risk of lung cancer in a population-based
prospective cohort study.METHODS
Study Design
Data for this prospective cohort study was derived from three
sub cohorts from the ongoing prospective Rotterdam Study (29).
The Rotterdam study started its first cohort in 1990 (RS-I) and
has expanded with two additional cohorts in 2000 (RS-II) and
2006 (RS-III), consisting of participants living in the district of
Ommoord in the city of Rotterdam. At the start of each cohort
and subsequently every 3 to 4 year, all participants were
examined in detail. Participants were interviewed at their home
(2 h) and afterwards, trained staff exposed these participants to
multiple measurements in a special research facility centre (5 h).
An overview of the various cohorts with the various follow-up
measurements and starting dates were described elsewhere (29).
A written Informed consent was signed by all participants. The
institutional review board of the Erasmus MC as well as the
review board of The Netherlands Ministry of Health Welfare and
Sports approved the Rotterdam Study (29).
Study Population and Exclusion Criteria
The population in this study consisted of participants from the
first three cohorts that started in 1990 (RS-I), 2000 (RS-II), and
in 2006 (RS-III). By 2008, the total number of participants in the
Rotterdam Study at baseline consisted of 14,926 participants
aged 45 or over. In this study we excluded participants without
all investigated anthropometric or lifestyle measurements at
baseline from the initial cohort (N= 5,237). Therefore, the
number of participants at baseline was equal to 9,689. All
participating women were postmenopausal.
Assessment of Lung Cancer
The primary outcome of interest was incident lung cancer. Two
research physicians independently assessed the diagnosis of
cancer based on medical records obtained through general
practitioners and hospital discharge letters. Additional
information was collected through linkage with the Dutch
Hospital Data, National Cancer Registry, and Dutch pathology
database (PALGA). Only cases confirmed by pathology were
used. Cases of mesothelioma were not included in the definition
of cancer for these analyses. Lung cancer was classified according
to the International Classification of Diseases tenth edition
(C34.2, C34.3). In case of discrepancy, consensus was obtained
through consultation with a cancer epidemiologist. Follow-up of
cancer registration was completed up to January 1, 2014.
Anthropometric Measurements
The anthropometric measurements Body Mass Index (BMI),
Waist circumference (WC), Waist-to-Hip Ratio (WHR), and A
Body Shape Index (ABSI) were measured in the research centre
by trained staff during regular on site visits every 3–4 years.November 2020 | Volume 10 | Article 591110
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squared height (m2). Height and weight were measured without
shoes and heavy outerwear, using calibrated SECA-measurement
scales. BMI was categorised as normal, overweight, and obese
with the corresponding cut offs <25, 25–30, and >30 kg/m²,
respectively (24). Since the underweight class (<18.5 kg/m²)
contained only five lung cancer cases, we merged this class
with the normal weight class to warrant the sample size.
WC (cm) was measured with a flexible measuring tape at the
level halfway between the lower rib margin and the iliac crest in
standing position, without heavy outerwear, empty pockets, and
calm exhaling. According to recommendations of the WHO
(World Health Organization), WC was categorised as normal,
increased, and substantially increased with the corresponding cut
offs <80, 80–88, and >88 cm, respectively, in females and <94,
94–102, and >102 cm, respectively, in males (24).
WHR was defined as the WC (in cm) divided by the Hip
Circumference (HC). HC (in cm) was measured as the
maximum circumference over the nates. According to
recommendations of the WHO, WHR was categorised as
normal, increased, and substantially increased with the
corresponding cut offs <0.80, 0.80–0.85, and >0.85 respectively,
in females and <0.95, 0.95–1.00 and >1.00, respectively, in males
(24). We standardised the continuous WHR values into age
(continuous) and sex adjusted z-scores, specific to the sample
of analysis.
ABSI (A Body Shape Index) was calculated as WC/(BMI2/3×
height1/2) (26). To compare low ABSI-values with higher ABSI-
values, we divided ABSI into tertiles. As with WHR, we
standardised the continuous ABSI values into age (continuous)
and sex adjusted z-scores, specific to the sample of analysis.
Covariate Assessment
Covariates of interest were derived from the existing literature and
measured at baseline. We considered the following covariates as
important due to their relation with the anthropometric
measurements and the risk of lung cancer: age; employment;
highest educational level; marital status; sex; ever diagnosed for
cancer; smoking status; pack years; physical activity; WCRF/AICR
(World Cancer research Fund/American Institute for Cancer
Research) adherence score; alcohol consumption.
Paid employment (yes/no), educational level (high: higher
general education or university/low: primary education or
intermediate vocational), marital status, (partner/no partner)
and sex (men/women) ever diagnosed for cancer (yes/no) and
smoking status (never, ever, current), together with the
corresponding cigarettes in pack years (continuously), were
self-reported during the home interviews. Physical activity (30,
31) was measured in MET-hours and assessed with an adapted
version of the Zutphen Physical Activity questionnaire (32). For
the current analyses, we standardised the continuous MET hours
per week values into z-scores, specific to the sample of
analysis. The WCRF/AICR adherence score contained five
recommendations for cancer prevention including: avoiding
energy-dense foods, sugar-containing drinks, red and
processed meat, and stimulating fruit and vegetables, dietary
fiber, and vitamin supplementation. A minimum sum score of 0Frontiers in Oncology | www.frontiersin.org 3points indicated that none of the recommendations was met and
a maximum sum score of 5 indicated that all recommendations
were fully met. Dietary intake items as well as alcohol
consumption (grams of ethanol per day) were measured by
using the validated food frequency questionnaire (FFQ) (33).
Statistical Analysis
We used Cox proportional hazards regression to analyse the
association between BMI, WC, WHR, and ABSI values with the
risk of lung cancer. Both continuous and categorical analyses
were performed. For all categorical variables, we used the lowest
category as reference category. Results of the Cox-regression
analyses were presented as hazard ratios (HRs) with the
corresponding 95% confidence intervals (CI). The underlying
time axis of the Cox-regression model was the follow-up time,
starting at baseline until the first diagnosis of lung cancer, death,
or end of the study period, whichever came first. Results of the
Cox-regression analysis were presented in a crude model
(model 1) which included the association between the main
determinant and the outcome variable, adjusted for sex and age,
as well as a multivariable model, adjusting the association for all
(potential) confounders at baseline (model 2). Furthermore, we
used the Wald-test to calculate the overall p-for trend for the
categorical variables. We added an interaction term between
the covariates and the underlying follow-up time to test for the
proportional hazard assumption. In addition to the baseline
measurements, we analysed the mean differences between
baseline and follow-up of BMI, WC, WHR, and ABSI in
relation to the risk of lung cancer to examine whether the
association might change over time. Within these associations,
the baseline measurement of each anthropometric measure-
ment was added to account for potential regression to the mean
(34). These mean differences were calculated by using a paired
sample t-test.
We tested for effect modification by sex (men/women),
smoking status (never, ever current), and pack years
(continuous). We added an interaction term between the main
determinant(s) and sex (determinant*sex) in an unadjusted Cox-
regression model. Whenever the interaction term was significant,
the results were presented categorized by sex, smoking status or
stratified by the median of pack years.
In this study, we performed two sensitivity analyses. First, we
systemically excluded lung cancer cases within the first 5, 7.5, and
10 years of follow-up to examine whether reverse causation could
influence the association between BMI at baseline and the risk of
lung cancer. Second, to assess the role of residual confounding by
smoking, the association between BMI and the risk of lung cancer
was stratified for never, ever and, current smokers.
The possibility of non-linear associations between the
anthropometric measurements BMI, WC, WHR and, ABSI
with the risk of lung cancer were assessed by using data driven
natural cubic splines as suggested by Durrleman et al. (34).
Degrees of freedom were determined on the basis of the lowest
Akaike’s information criterion (AIC) value. Likelihood ratio tests
(LRTs) were performed to ascertain whether a non-linear model
suited the data better than a linear model. Whenever the LRTs
showed a significant result, the effect estimates were separated forNovember 2020 | Volume 10 | Article 591110
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based on the knots in the cubic spline.
All missing values, except for the outcome variable, were
imputed by using the Markov chain Monte Carlo (MCMC)
method. After the imputation procedure, the resulting tenFrontiers in Oncology | www.frontiersin.org 4datasets were pooled and an average of the imputed data was
calculated. The pooled data was used to conduct all analyses in
this study. In this study, p-values less than 0.05 (two-sided) were
considered as statistically significant. For the non-linear
Likelihood-ratio (LR) test we used R-statistics version 4.4.3. InTABLE 1 | Baseline characteristics by cohort in the Rotterdam Study.
Characteristic Total baseline, n = 9689 RS-I, n = 5397 RS-II, n =1616 RS-III, n = 2676 P-for trend
Follow-up (years) mean ± SD 13.2 (6.8) 16.0 (7.0) 13.5 (3.4) 7.3 (1.4) <0.001
Sex, n (%)
Men 4082 (42.1) 2217 (41.0) 743 (46.0) 1122 (41.9) 0.002
Women 5607 (57.9) 3180 (59.0) 873 (54.0) 1554 (58.1)
Age (years), mean ± SD 64.1 ± 8.7 67.7 ± 7.8 63.8 ± 7.3 57.1 ± 6.6 <0.001
Body Mass Index (kg/m2), mean ± SD 26.8 ± 4.0 26.3 ± 3.6 27.3 ± 4.1 27.5 ± 4.5 <0.001
Body Mass Indexa, n (%)
Normal weight 3374 (34.9) 2068 (38.3) 478 (29.6) 828 (30.9) <0.001
Overweight 4594 (47.4) 2560 (47.4) 795 (49.2) 1239 (46.3)
Obese 1721 (17.7) 769 (14.3) 343 (21.2) 609 (22.8)
Waist circumference (cm), mean ± SD 91.6 ± 11.8 90.2 ± 11.0 94.0 ± 11.9 93.1 ± 11.8 <0.001
Waist circumferenceb, n (%)
Normal risk 2993 (30.9) 1856 (34.4) 400 (24.8) 737 (27.5) <0.001
Increased risk 2920 (30.1) 1617 (30.0) 513 (31.7) 790 (29.5)
Substantially increased risk 3776 (39.0) 1924 (35.6) 703 (43.5) 1149 (43.0)
Waist-to-Hip Ratio, mean ± SD 0.895 (0.092) 0.903 (0.092) 0.911 (0.091) 0.868 (0.086) <0.001
Waist-to-Hip Ratioc, n (%)
Normal risk 3468 (35.8) 1704 (31.6) 466 (28.8) 1298 (48.5) <0.001
Increased risk 2466 (25.5) 1344 (24.9) 442 (27.4) 680 (25.4)
Substantially increased risk 3755 (38.7) 2349 (43.5) 708 (43.8) 698 (26.1)
ABSI, mean ± SD 0.079 (0.0058) 0.080 (0.0063) 0.080 (0.0054) 0.0785(0.0060) <0.001
ABSI, n (%)
Tertile 1 3229 (33.3) 1896 (35.1) 412 (25.5) 921 (34.4) <0.001
Tertile 2 3230 (33.3) 1631 (30.2) 552 (34.2) 1047 (39.1)
Tertile 3 3230 (33.3) 1870 (34.7) 652 (40.3) 708 (26.5)
Physical activity (MET hours), median (IQR) -0.170 (1.22) -0.150 (1.3) -0.106 (1.2) -0.269 (1.1) 0.135
Alcohol intake (g/day), median (IQR) 5.29 (17.3) 3.45 (14.7) 8.39 (21.1) 7.95 (18.3) <0.001
Smoking status, n (%)
Never smoker 3117 (32.2) 1814 (33.6) 470 (29.0) 833 (31.1) 0.002
Ever smoker 4279 (44.2) 2327 (43.1) 771 (47.7) 1181 (44.1)
Current smoker 2293 (23.6) 1256 (23.3) 375 (23.3) 662 (24.8)
Pack-years, median (IQR)
Ever smoker 15.0 (26.6) 18.7 (31.2) 13.3 (26.8) 11.3 (21.1) <0.001
Current smoker 26.3 (29.4) 30.0 (26.8) 20.7 (37.3) 20.5 (34.8) <0.001
Education, n (%)
High 4207 (43.4) 1981 (36.7) 863 (53.4) 1473 (55.0) <0.001
Low 5482 (56.6) 3416 (63.3) 753 (46.6) 1203 (45.0)
Employed, n (%)
Yes 2696 (27.8) 666 (12.3) 394 (24.4) 1636 (61.1) <0.001
No 6993 (72.2) 4731 (87.7) 1222 (75.6) 1040 (38.9)
Partner, n (%)
Yes 7090 (73.2) 3744 (69.4) 1230 (76.1) 2116 (79.1) <0.001
No 2599 (26.8) 1653 (30.6) 386 (23.9) 560 (20.9)
WCRF adherence, mean ± SD
DM, n (%)
3.54 (0.8) 3.48 (0.8) 3.77 (0.8) 3.51 (0.8) <0.001
Yes 1226 (12.7) 781 (14.5) 203 (12.6) 242 (9.0) <0.001
No 8463 (87.3) 4616 (85.5) 1413 (87.4) 2434 (91.0)
Ever diagnosed for cancer, n (%)
Yes 1448 (15.0) 1015 (18.8) 195 (12.0) 278 (10.4) <0.001
No 8241 (85.0) 4382 (81.2) 1421 (88.0) 2438 (89.6)November 2020 | Volume 10 | ArLC, lung cancer; SD, Standard Deviation; IQR, Interquartile Range; BMI, Body Mass Index; WC, Waist circumference; WHR, Waist-to-Hip Ratio; ABSI, A Body Shape Index; MET,
Metabolic Equivalents; WCRF, World Cancer Research Fund; DM, Diabetes Mellitus.
aBMI was categorised as normal, over weighted, and obese with the corresponding cut offs <25, 25–30, and >30, respectively.
bWaist circumference was categorised as normal, increased, and substantially increased with the corresponding cut offs <80, 80-88, and >88 cm, respectively, in females and <94, 94-
102, and >102 cm, respectively, in males.
cWaist-to-Hip-Ratio was categorised as normal, increased, and substantially increased with the corresponding cut offs <0.80, 0.80-0.85, and >0.85, respectively, in females and <0.95,
0.95-1.00, and >1.00, respectively, in males.ticle 591110
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Service Solutions (SPSS) version 24.0.RESULTS
Study Population Characteristics
Table 1 shows the main baseline characteristics of the study
population (n= 9,689). Within a mean follow-up of 13.2 years,
319 participants developed lung cancer. Most participants
developed lung cancer in cohort 1 (88.7%) within a mean
follow-up of 16.0 years. According to the guidelines of the
WHO, most of the participants showed a substantially
increased WC in all cohorts. Similarly, this trend was also
observed for WHR, except for RS-III. Participants in RS-III
showed the lowest age, WHR, ABSI, but the highest BMI
on average.
Anthropometric Measurements at Baseline
and the Risk of Lung Cancer
As shown in Table 2, an 1 kg/m2 increase of BMI was associated
with a reduced risk of lung cancer, after adjustment for sex and
age (HR 0.95, 95% CI: 0.92–0.98) and after full adjustment for
sex, age, cohort, physical activity, alcohol intake, pack-years,Frontiers in Oncology | www.frontiersin.org 5education, WCRF adherence score, and diabetes mellitus (HR
0.94, 95% CI: 0.91–0.97). This corresponding inverse trend was
also observed for the normal BMI group (reference group,
BMI<25) compared with the high and obese group, after
adjustment for sex and age (High: HR 0.76 95% CI: 0.60–0.96)
(Obese: HR 0.68 95% CI: 0.47–0.99) and in the fully adjusted
model (High: HR 0.72 95% CI: 0.56–0.91) (Obese: HR 0.61 95%
CI: 0.41–0.89). Furthermore, 1 cm of WC (HR 1.03 95% CI:
1.01–1.06) and one standard deviation increase of WHR (HR
1.23 95% CI: 1.09–1.38) and ABSI (HR 1.17 95% CI: 1.05–1.30)
were positively associated with a 3%, 23%, and 17% higher risk of
lung cancer respectively, after full adjustment for confounders.
Similar results were observed when WHR (HR 1.66 95% CI:
1.21–2.26, P-for trend = 0.06) and ABSI (HR 1.50 95% CI: 1.05–
2.12, P-for trend = <0.001) were analyzed categorically.
Sensitivity Analyses
Table 3 shows that the inverse association between BMI and the
risk of lung cancer persisted after excluding lung cancer cases in
the first 5, 7.5, and 10 years of follow-up, before and after full
adjustment for sex, age, cohort, physical activity, alcohol intake,
pack-years, education, WCRF adherence score, and diabetes
mellitus. Moreover, in both models, the inverse association
remained stable as the number of excluded follow-up yearsTABLE 2 | Hazard ratio’s (95% CI) for the association between BMI (kg/m2), WC (cm), WHR, and ABSI with the risk of lung cancer.
Anthropometric measurement Number of LC cases Model 1 HR, 95% CI Model 2 HR, 95% CI
Body Mass Indexa (kg/m2)
Normal 138 1.00 Referent 1.00 Referent







Continuous 319 0.95 (0.92–0.98)* 0.94 (0.91–0.97)*
Waist circumferenceb (cm)
Normal risk 123 1.00 Referent 1.00 Referent







Continuous 319 1.02 (1.00–1.04)* 1.03 (1.01–1.05)*
Waist-to-Hip Ratioc
Normal risk 96 1.00 Referent 1.00 Referent







Continuous 319 1.18 (1.07–1.31)* 1.23 (1.09–1.38)*
ABSI
Tertile 1 70 1.00 Referent 1.00 Referent







Continuous 319 1.19 (1.09–1.31)* 1.17 (1.05–1.30)*November 2020 | VolumHR, Hazard Ratio; CI, Confidence Interval; LC, lung cancer; ABSI, A Body Shape Index.
Model 1: Adjusted for sex and age.
Model 2: Adjusted for sex, age, cohort (RS-I/RS-II/RS-III), physical activity (continuous), alcohol intake (continuous), pack-years (continuous), education (high/low), WCRF adherence score
(continuous), diabetes mellitus (yes/no). WC and WHR were additionally adjusted for BMI.
aBMI was categorised as normal, over weighted, and obese with the corresponding cut offs <25, 25–30, and >30, respectively.
bWaist circumference was categorised as normal, increased, and substantially increased with the corresponding cut offs <80, 80-88, and >88 cm, respectively, in females and <94, 94–
102, and >102 cm, respectively, in males.
cWaist-to-Hip-Ratio was categorised as normal, increased, and substantially increased with the corresponding cut offs <0.80, 0.80-0.85, and >0.85, respectively, in females and <0.95,
0.95–1.00, and >1.00, respectively, in males.
*Underlined values indicate a statistically significant association.e 10 | Article 591110
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risk of lung cancer, stratified for never, ever, and current
smokers. Before and after full adjustment for confounders,
BMI was not associated with the risk of lung cancer in never,
ever, and current smokers.
Anthropometric Mean Differences and the
Risk of Lung Cancer
Within a mean follow-up of 11.6 years from baseline until the
next follow up measurement, in which 173 lung cancer cases
were identified, the mean BMI (-0.58 kg/m2, 95% CI: -0.62 –
-0.53), WC (-2.79 cm, 95% CI: -3.00 – -2.58), and WHR (-0.016
95% CI: -0.019 – -0.014) decreased, whereas the ABSI mean
(0.0350 95% CI: 0.0348 – 0.0352) increased. Table 5 provides the
hazard ratios for the associations between the mean differences of
BMI, WC, WHR, and ABSI at baseline and follow-up with the
risk of lung cancer. None of the associations between the mean
differences at baseline and follow-up for BMI, WC, WHR, and
ABSI with the risk of lung cancer were significant.
Additional Analyses
In all Cox regression models, there was no significant interaction
between follow-up time and BMI, WC, WHR, and ABSI.
Therefore, the proportional hazard assumption was met for all
associations. No significant interactions were observed between
BMI, WC, WHR, and ABSI with smoking status and sex (data
not shown). Furthermore, no significant interactions were found
for BMI, WC, WHR, and ABSI with pack years of smoking (data
not shown). Figure 1 shows the relation between 1-unit increaseFrontiers in Oncology | www.frontiersin.org 6of BMI, WC, WHR, and ABSI with the risk of lung cancer for
9689 participants, including 319 lung cancer cases. None of the
Likelihood-ratio (LR) tests between WC (p = 0.99, df =1), WHR
(p = 0.09, df =1) or ABSI (p = 0.46, df =1) and the risk of lung
cancer suggested a non-linear relationship. In contrast, the LR
test between BMI (p = 0.04, df =1) and the risk of lung cancer did
suggest a non-linear relationship. More specifically, the inverse
association between BMI and lung cancer risk was only linear in
non-obese participants whereas the curve flattened in
obese participants.DISCUSSION
In this prospective cohort study, we found that BMI was
inversely associated with the risk of lung cancer. In contrast to
BMI, an increased WC, WHR, and ABSI were associated with a
higher risk of lung cancer. Additionally, we found evidence
regarding a non-linear association between BMI and the risk of
lung cancer, which indicated that the inverse association between
BMI and lung cancer risk was only present in non-obese
participants, whereas an increase in WC, WHR, and, ABSI
showed a linearly higher risk of lung cancer.
Our results showed that a higher BMI was associated with a
reduced risk of lung cancer which is in line with two meta-
analyses (36, 37) and two pooled analyses (9, 38). Although these
results seem to be consistent, this inverse association is in conflict
with the hypothesis that suggests that obesity is a risk factor for
lung cancer (39, 40). Residual confounding by smoking and
reverse causation are proposed explanations for this inverse
association (41, 42). Interestingly we found that the inverse
association persisted after excluding lung cancer cases during
the first 5, 7.5, and 10 years of follow-up. Our findings are in
agreement with several other studies that attempted to address
the role of reverse causation by excluding the lung cancer cases
during the first years of follow-up. However, two other studies
suggested that the strength of association between BMI and the
risk of lung cancer diluted after excluding lung cancer casesTABLE 4 | Hazard ratio’s (95% CI) for BMI (kg/m2) and the risk of lung cancer in







Never smokers 33 0.97 (0.90–1.07) 0.97 (0.89–1.07)
Ever smokers 102 0.99 (0.93–1.06) 0.96 (0.89–1.03)
Current smokers 167 0.98 (0.93–1.02) 0.98 (0.94–1.03)HR, Hazard Ratio; CI, Confidence Interval; LC, lung cancer; ABSI, A Body Shape Index.
Model 1: Adjusted for sex and age.
Model 2: Adjusted for sex, age, cohort (RS-I/RS-II/RS-III), physical activity (continuous),
alcohol intake (continuous), pack-years (continuous), education (high/low), WCRF
adherence score (continuous), and diabetes mellitus (yes/no).TABLE 5 | Hazard ratio’s (95% CI) for the mean differences of BMI (kg/m2), WC








Continuous 173 0.99 (0.89–1.09) 1.00 (0.91–1.10)
Waist circumference
Continuous 173 1.00 (0.98–1.02) 1.01 (0.98–1.03)
Waist-to-Hip Ratio
Continuous 173 1.03 (0.89–1.19) 1.02 (0.86–1.20)
ABSI
Continuous 173 0.99 (0.86–1.15) 0.92 (0.77–1.10)November 2020 | Volume 10HR, Hazard Ratio; CI, Confidence Interval; LC, lung cancer; ABSI, A Body Shape Index.
Model 1: Adjusted for sex and age.
Model 2: Adjusted for sex, age, cohort ((RS-I/RS-II/RS-III), physical activity (continuous),
alcohol intake (continuous), pack-years (continuous), education (high/low), WCRF
adherence score (continuous), and diabetes mellitus (yes/no). WC and WHR were
additionally adjusted for difference in BMI between baseline and follow-up. Thereby, all
hazard ratios were adjusted for their own baseline measurement to correct for regression
to the mean (35).TABLE 3 | Hazard ratio’s (95% CI) for BMI (kg/m2) with the risk of lung cancer
after excluding lung cancer cases during the first 5, 7.5, and 10 years of follow-








5 245 0.95 (0.91–0.99)* 0.94 (0.90–0.98)*
7.5 204 0.95 (0.91–0.99)* 0.94 (0.90–0.98)*
10 162 0.95 (0.91–1.00)* 0.95 (0.90–0.99)*HR, Hazard Ratio; CI, Confidence Interval; LC, Lung Cancer.
Model 1: Adjusted for sex and age.
Model 2: Adjusted for sex, age, cohort (RS-I/RS-II/RS-III), physical activity (continuous),
alcohol intake (continuous), pack-years (continuous), education (high/low), WCRF
adherence score (continuous), and diabetes mellitus (yes/no).
*Underlined values indicate a statistically significant association.| Article 591110
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causation might play a role (10, 11). However, these two
studies included mainly women, which can explain the
different results because survival and clinical presentation for
lung cancer differs among men and women (43). We also
assessed the association between change in BMI and the risk of
lung cancer between baseline and follow-up. Nonetheless, we did
not find a significant association between a difference in BMI and
the risk of lung cancer over time, which contradicts the role of
reverse causation. Additionally, we assessed whether the
relationship between BMI and the risk of lung cancer had a
non-linear shape. We found evidence for a non-linear
association between BMI and the risk of lung cancer
suggesting that the inverse association only applies for
participants without obesity. Previous studies showed that
obesity is unbeneficial for developing lung cancer (20, 38),
which could flattened the BMI-lung cancer curve for this
group in our population.
An explanation for the inverse association between BMI and
the risk of lung cancer in those without obesity may come from
residual confounding by smoking. In the current study we found
no association between BMI and the risk of lung cancer among
never, ever, or current smokers. Several other studies which
stratified the association for smoking found similar results (15–
19). However, similar to our study, these studies had a relatively
small number of lung cancer cases because lung cancer is quiteFrontiers in Oncology | www.frontiersin.org 7rare in subjects without a history of smoking. Studies with larger
sample sizes showed contrary results: a recent meta-analysis of
19 studies including 15 million never smokers and a pooled
analysis of 12 studies containing almost 700,000 never smokers,
showed that the inverse association also persisted in never
smokers (9, 20). Thus, although the results in this study cannot
fully rule out the presence of residual confounding by smoking,
on the basis of our results combined with previous meta-
analyses, smoking may not fully explain the inverse association
between BMI and the risk of lung cancer.
An alternative biological explanation for the inverse
association between BMI and the risk of lung cancer can be
the storage of common environmental genotoxicants in fat
tissue. Lipophilic genotoxicants such as polycyclic aromatic
hydrocarbons (PAHs) that are derived from smoking or
occupational exposure influence the development of lung
cancer through DNA damage (44). Previous work has
suggested that an individual’s BMI or fat tissue influences the
metabolism of PAHs, in which lower levels of PAH-DNA
adducts are found in the circulation of obese individuals (45).
This may imply that individuals with lower fat tissue may have a
higher exposure to these lipophilic carcinogens.
Our study found that WC and WHR were positively
associated with the risk of lung cancer, consistent with other
studies (9, 21). However, other studies that investigated the
association between WC and the risk of lung cancer foundFIGURE 1 | Natural cubic splines in a standard cox-regression model with knots at 22, 27, 34 and 72, 92, 112, and -1.5, 0, 1.5 and -1.5, 0, 1.5 for BMI, WC,
WHR, and, ABSI respectively. The blue line represents the hazard ratios for the risk of lung cancer with the corresponding 95% confidence interval. Hazard ratios
were adjusted for sex, age, cohort (RS-I/RS-II/RS-III), physical activity (continuous), alcohol intake (continuous), pack-years (continuous), education (high/low), WCRF
adherence score (continuous), and diabetes mellitus (yes/no). WC and WHR were additionally adjusted for BMI.November 2020 | Volume 10 | Article 591110
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participants found an inverse association between WC and the
risk of lung cancer (23). Unlike our study, this study did not
correct the analyses for BMI, which can explain the
contradictory results. Another prospective cohort study found
no association between WC and the risk of lung cancer (22).
Although WHR and WC are both measurements of abdominal
obesity, the association with the risk of lung cancer seems only
consistent for WHR studies (9, 21). These dissimilar results
could be explained by the fact that WHR has a stronger
correlation with visceral fat when compared to WC (46).
Increased visceral fat is positively associated with the risk of
cancer (47), as visceral fat promotes inflammation and insulin
resistance and may therefore create a pro-tumorigenic
environment (48).
The findings is this study showed that ABSI was positively
associated with the risk of lung cancer. Although this is the first
study that examined the association between ABSI and the risk
of lung cancer, another study among 200 adults with
overweight found an inverse association between ABSI and
FFMI (Fat Free Mass Index) (27), indicating that a decreased
ABSI is associated with a higher FFMI when compared to
higher ABSI values. A low FFMI may be an indicator for a
higher risk of lung cancer as progressive loss of muscle mass is
the main characteristic of lung cancer cachexia (49). However,
since we focussed on incident lung cancer and did not find
indications of reverse causality, our results on ABSI may not be
explained by lung cancer cachexia. Another study among
elderly found that in men, ABSI was positively associated
with FM (Fat Mass) and thereby negatively associated with
FFM (Fat Free Mass) (50). This study suggests that the positive
association between ABSI and the risk of lung cancer may be
dedicated to an increased FM, and may therefore support the
hypothesis of body fatness and in particular abdominal obesity
as a risk factor for lung cancer (50). Moreover, ABSI also shows
a positive correlation with visceral fat (51). As mentioned
earlier, increased visceral fat is associated with cancer
progression (47) and may create a pro-tumorigenic environment
(48). Therefore, more research is needed to identify the specific
roles of visceral adiposity and FM and FFM in the relation to
incident lung cancer as the VAT/SAT (Visceral and Subcutaneous
Adipose Tissue) ratio is an independent predictor for non-small-
cell lung cancer (52).
Although we found associations between baseline BMI,
WC, WHR, and ABSI with the risk of lung cancer, we found
no association for the mean differences between baseline and
follow-up of BMI, WC, WHR, and ABSI with the risk of lung
cancer. Another prospective cohort study among 8000 Dutch
participants found that a moderate short-term annual
decrease (-0.10 – -0.50 kg/m2/year) of BMI, was associated
with a reduced risk of lung cancer in women (53). However,
due to a lack of available data, this study could not fully correct
the association between BMI and the risk of lung cancer for
physical activity and alcohol consumption, both important
confounders for the association between obesity and the risk
of lung cancer. The non-significant results in this study can beFrontiers in Oncology | www.frontiersin.org 8explained in multiple ways. First, it should be mentioned that
within the current study, anthropometric measures become
less reliable during ageing due to shrinking and changes in
body composition (i.e. loss of fat free mass) (54) and could
have influenced the non-significant results because lung
cancer has a long latency period. Secondly, as people
become older, it is more likely that low body mass is
reflected by a low muscle mass instead of a low fat mass (55,
56). This implies that BMI, WC, WHR, and ABSI may give an
underestimation of the (abdominal) fat mass in a person.
Consequently, these anthropometric measurements of
body size and body shape become less valid. Therefore,
future studies including larger sample sizes, longer years of
follow-up, data on changes of covariates over time, and
measurements that can distinguish fat and muscle mass, are
needed to elucidate the role of body size and body shape over
time in an appropriate manner.
An important strength of this study is that all anthropometric
measurements are performed by trained staff in a special
designed research centre according to a consistent protocol.
Therefore, the chance of information bias in this study is
minimal when compared to other studies (57). A second
strength is the follow-up of 25 years. The Rotterdam Study has
one of the longest follow-up in years when compared to other
studies, which allowed us to assess the role of reverse causation
over a longer time period.
This study has also some limitations. First, the number of
incident lung cancer cases in this study was relatively low. As a
result we could not perform extensive subgroup analysis since
the association between obesity and lung cancer may differ for
tumour histological type, ethnic origin, and sex (9). For
example, non-smokers develop more often adenocarcinomas
and different risk factors (e.g. genetic as well as environmental)
can play a role (58). Furthermore, we were unable to conduct
sensitivity analyses on the basis of COPD at baseline because of
the small number of cases in our cohort. Despite the fact that
only 19 lung cancer cases had COPD, the results preclude any
conclusions regarding specific groups that may be more or less
vulnerable to the consequences of (abdominal) obesity on lung
cancer. Due to a lack of detailed data, we were also unable to
correct our analysis for metabolic dysfunctions at baseline with
the exception of diagnosis of type 2 diabetes. As metabolic
dysfunctions are associated with central adiposity as well as
lung cancer risk (59), the influence of early stage metabolic
disturbances cannot be ruled out. Further, we did not have
detailed measures on FFM specifically (eg. By DXA) to confirm
that the association between ABSI and lung cancer is explained
by sarcopenia, which has been found to be a predictor for lung
cancer prognosis (60) as well as metabolic dysfunction (61). A
second limitation was that the covariates in this study were
only measured at baseline. The analysis of the mean differences
between baseline and follow-up was therefore only adjusted for
baseline covariables. Important covariates such as smoking
and physical activity may have changed during follow-up
and could have influenced our results. Additionally, these
important covariables were self-reported, which usuallyNovember 2020 | Volume 10 | Article 591110
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underestimation of alcohol consumption (62). A third
limitation is that the results in this study were mainly based
on a population of traditionally Dutch origin. A pooled analysis
found that the association between BMI and lung cancer
was stronger among blacks when compared to whites
(9). Hence, we may have underestimated the effect in our
study when compared to studies which contained more
diverse ethnic origins.
In conclusion, we found an inverse association between BMI
and the risk of lung cancer. In contrast, WC, WHR and ABSI
are positively associated. We found evidence that reverse
causation may serve as an explanation for the inverse
association between BMI and lung cancer. Future research
with larger sample sizes should focus on the role of visceral fat
and the distinction between fat mass from fat free mass, using
more advanced measuring tools to get a better understanding of
the underlying biological mechanisms.DATA AVAILABILITY STATEMENT
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